In addition, Zhou et al. [11] examined the contribution of SEMA4D to tumor-induced angiogenesis when compared to VEGF and suggested that targeting these proteins might represent a complementary or parallel mode of treatment for anti-angiogenic therapy of HNSCC and other solid tumors exhibiting insensitivity of anti-VEGF therapy. The gene discussed is SEMA4D; the disease is head and neck squamous cell carcinoma.